ArticleOncogene2026
CAF-derived exosomes inhibit ferroptosis via GALNT14-mediated O-GalNAcylation of SLC7A11 in colorectal cancer.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
In the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs)-the dominant stromal component-actively shape cancer progression through exosome-mediated communication. Here, we identify hsa_circ_0003892 (circLDLR), a CAF-derived circRNA, as a key factor associated with poor prognosis in colorectal cancer (CRC). During interactions between CAFs and CRC cells, circLDLR is packaged into exosomes and transferred to tumor cells, where it enhances proliferation and metastasis primarily by reducing susceptibility to ferroptosis. Mechanistically, circLDLR stabilizes Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) by protecting it from ZNRF2-mediated ubiquitination and degradation. This stabilization promotes the O-GalNAcylation of Solute Carrier Family 7 Member 11 (SLC7A11) at Ser26, facilitating its membrane localization and thereby suppressing ferroptosis in CRC cells. Additionally, we demonstrate that the RNA-binding protein EIF4A3 facilitates circLDLR biogenesis within CAFs. Taken together, our study reveals that CAF-derived circLDLR confers ferroptosis resistance and promotes CRC progression via the GALNT14/SLC7A11 axis. Consequently, disrupting exosomal circLDLR transfer between CAFs and CRC cells may offer a promising therapeutic strategy for CRC. Schematic diagram of the mechanism by which CAF-derived circLDLR promotes CRC progression through ferroptosis regulation. In the tumor microenvironment, CAFs highly express circLDLR, whose biogenesis is facilitated by EIF4A3-mediated splicing of LDLR pre-mRNA. circLDLR is then packaged into exosomes and transferred to CRC cells. Within CRC cells, circLDLR specifically binds to GALNT14 and inhibits its ubiquitination and degradation mediated by ZNRF2, thereby enhancing GALNT14 protein stability. Stabilized GALNT14 promotes O-GalNAcylation of SLC7A11 at Ser26, facilitating its membrane localization and increasing cystine uptake. The elevated cystine metabolism enhances GSH production, thereby suppressing ferroptosis and driving CRC cell proliferation and progression.
Indexed as
Identifiers
42414656What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.